Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein

[1]  X. Gallart‐Palau,et al.  Alzheimer’s disease progression characterized by alterations in the molecular profiles and biogenesis of brain extracellular vesicles , 2020, Alzheimer's Research & Therapy.

[2]  B. Puig,et al.  Transgenic Overexpression of the Disordered Prion Protein N1 Fragment in Mice Does Not Protect Against Neurodegenerative Diseases Due to Impaired ER Translocation , 2020, Molecular Neurobiology.

[3]  L. Ciccone,et al.  The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1 , 2020, Molecules.

[4]  R. Vandenberghe,et al.  Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: relationship with clinical phenotypes , 2020, Acta Neuropathologica Communications.

[5]  M. Frosch,et al.  PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins , 2019, Acta Neuropathologica.

[6]  M. Rowan,et al.  Soluble tau aggregates inhibit synaptic long-term depression and amyloid β-facilitated LTD in vivo , 2019, Neurobiology of Disease.

[7]  S. Strittmatter,et al.  Anti‐PrPC antibody rescues cognition and synapses in transgenic alzheimer mice , 2019, Annals of clinical and translational neurology.

[8]  S. Strittmatter,et al.  Rescue of Transgenic Alzheimer’s Pathophysiology by Polymeric Cellular Prion Protein Antagonists , 2019, Cell reports.

[9]  K. Ando,et al.  Amyloid-β pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo , 2019, Acta Neuropathologica.

[10]  S. Strittmatter,et al.  Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss , 2018, The Journal of Neuroscience.

[11]  Quanzheng Li,et al.  Neurogenetic contributions to amyloid beta and tau spreading in the human cortex , 2018, Nature Medicine.

[12]  M. Rowan,et al.  Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo , 2018, The Journal of Neuroscience.

[13]  W. Klein,et al.  The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade , 2018, Journal of Alzheimer's disease : JAD.

[14]  J. Götz,et al.  Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn , 2018, Journal of Alzheimer's disease : JAD.

[15]  M. Rowan,et al.  Extracellular Forms of Aβ and Tau from iPSC Models of Alzheimer’s Disease Disrupt Synaptic Plasticity , 2018, Cell reports.

[16]  S. Strittmatter,et al.  Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model , 2018, Neuropharmacology.

[17]  H. Arshad,et al.  The function of the cellular prion protein in health and disease , 2018, Acta Neuropathologica.

[18]  Bin Zhang,et al.  Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation , 2017, Nature Medicine.

[19]  E. Mandelkow,et al.  Interplay of pathogenic forms of human tau with different autophagic pathways , 2017, Aging cell.

[20]  I. Zerr,et al.  α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B , 2017, Nature Neuroscience.

[21]  S. Strittmatter,et al.  Conditional Deletion of Prnp Rescues Behavioral and Synaptic Deficits after Disease Onset in Transgenic Alzheimer's Disease , 2017, The Journal of Neuroscience.

[22]  J. Attems,et al.  Interactions of pathological proteins in neurodegenerative diseases , 2017, Acta Neuropathologica.

[23]  W. Noble,et al.  Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer’s disease , 2016, Acta neuropathologica communications.

[24]  A. Joshi,et al.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.

[25]  C. Betzel,et al.  Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta‐mediated neurotoxicity , 2016, Journal of neurochemistry.

[26]  P. Baatsen,et al.  Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo , 2016, Acta Neuropathologica.

[27]  J. Hodges,et al.  Early‐onset axonal pathology in a novel P301S‐Tau transgenic mouse model of frontotemporal lobar degeneration , 2015, Neuropathology and applied neurobiology.

[28]  A. Hill,et al.  The prion protein constitutively controls neuronal store-operated Ca2+ entry through Fyn kinase , 2015, Front. Cell. Neurosci..

[29]  S. DeArmond,et al.  Prion Disease Induces Alzheimer Disease–Like Neuropathologic Changes , 2015, Journal of neuropathology and experimental neurology.

[30]  P. Verstreken,et al.  Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation. , 2015, Cell reports.

[31]  J. Götz,et al.  Tau aggregation and its interplay with amyloid-β , 2014, Acta Neuropathologica.

[32]  C. V. von Arnim,et al.  Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. , 2014, Brain : a journal of neurology.

[33]  S. Strittmatter,et al.  Fyn kinase inhibition as a novel therapy for Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[34]  F. Wandosell,et al.  Cellular prion protein modulates β-amyloid deposition in aged APP/PS1 transgenic mice , 2013, Neurobiology of Aging.

[35]  Pei-Lin Cheng,et al.  Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway. , 2013, ACS chemical neuroscience.

[36]  A. McIntosh,et al.  Plin2 Inhibits Cellular Glucose Uptake through Interactions with SNAP23, a SNARE Complex Protein , 2013, PloS one.

[37]  S. Love,et al.  Prion Protein Is Decreased in Alzheimer's Brain and Inversely Correlates with BACE1 Activity, Amyloid-β Levels and Braak Stage , 2013, PloS one.

[38]  C. Masters,et al.  Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples , 2013, Acta Neuropathologica.

[39]  D. Bennett,et al.  The Complex PrPc-Fyn Couples Human Oligomeric Aβ with Pathological Tau Changes in Alzheimer's Disease , 2012, The Journal of Neuroscience.

[40]  M. Staufenbiel,et al.  Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice , 2012, Neurobiology of Aging.

[41]  K. Jellinger,et al.  Correlations between cortical and subcortical tau pathology , 2012, Neuropathology and applied neurobiology.

[42]  N. Leclerc,et al.  Interaction of Endogenous Tau Protein with Synaptic Proteins Is Regulated by N-Methyl-d-aspartate Receptor-dependent Tau Phosphorylation* , 2012, The Journal of Biological Chemistry.

[43]  A. Vortmeyer,et al.  Alzheimer Amyloid-β Oligomer Bound to Post-Synaptic Prion Protein Activates Fyn to Impair Neurons , 2012, Nature Neuroscience.

[44]  N. Hooper,et al.  Regulation of amyloid-β production by the prion protein , 2012, Prion.

[45]  N. Hooper,et al.  Cellular Prion Protein Expression Is Not Regulated by the Alzheimer's Amyloid Precursor Protein Intracellular Domain , 2012, PloS one.

[46]  M. Fändrich,et al.  High-molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain , 2012, Journal of cellular and molecular medicine.

[47]  M. Staufenbiel,et al.  Transgenic Expression of Intraneuronal Aβ42 But Not Aβ40 Leads to Cellular Aβ Lesions, Degeneration, and Functional Impairment without Typical Alzheimer's Disease Pathology , 2012, The Journal of Neuroscience.

[48]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[49]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[50]  M. Jucker,et al.  Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders , 2011, Annals of neurology.

[51]  Hidehiro Takahashi,et al.  Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques in the Alzheimer's disease brain , 2011, Neuropathology : official journal of the Japanese Society of Neuropathology.

[52]  H. Braak,et al.  Alzheimer’s pathogenesis: is there neuron-to-neuron propagation? , 2011, Acta Neuropathologica.

[53]  H. Braak,et al.  The pathological process underlying Alzheimer’s disease in individuals under thirty , 2011, Acta Neuropathologica.

[54]  John Q Trojanowski,et al.  A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. , 2010, The American journal of pathology.

[55]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[56]  S. Strittmatter,et al.  Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein , 2010, The Journal of Neuroscience.

[57]  D. Selkoe,et al.  The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. , 2010, Brain : a journal of neurology.

[58]  M. Gobbi,et al.  Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein , 2010, Proceedings of the National Academy of Sciences.

[59]  R. Nitrini,et al.  The dorsal raphe nucleus shows phospho‐tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset? , 2009, Neuropathology and applied neurobiology.

[60]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[61]  P. S. St George-Hyslop,et al.  p53-Dependent Transcriptional Control of Cellular Prion by Presenilins , 2009, The Journal of Neuroscience.

[62]  G. Zamponi.  Faculty Opinions recommendation of Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. , 2009 .

[63]  J. Velayos,et al.  The cellular prion protein and its role in Alzheimer disease , 2009, Prion.

[64]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[65]  G. Schellenberg,et al.  Tau isoform regulation is region‐ and cell‐specific in mouse brain , 2008, The Journal of comparative neurology.

[66]  Xiao-Fan Wang,et al.  Human tau protein forms complex with PrP and some GSS- and fCJD-related PrP mutants possess stronger binding activities with tau in vitro , 2008, Molecular and Cellular Biochemistry.

[67]  C. Sachse,et al.  Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils , 2007, Proceedings of the National Academy of Sciences.

[68]  M. Staufenbiel,et al.  Occurrence and co-localization of amyloid β-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice , 2007, Neurobiology of Aging.

[69]  N. Hooper,et al.  Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein , 2007, Proceedings of the National Academy of Sciences.

[70]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[71]  U. Landegren,et al.  Direct observation of individual endogenous protein complexes in situ by proximity ligation , 2006, Nature Methods.

[72]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[73]  H. Braak,et al.  The development of amyloid beta protein deposits in the aged brain. , 2006, Science of aging knowledge environment : SAGE KE.

[74]  N. Cairns,et al.  Expression of Cellular Prion Protein in the Frontal and Occipital Lobe in Alzheimer's Disease, Diffuse Lewy Body Disease, and in Normal Brain: An Immunohistochemical Study , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[75]  Kurt Bürki,et al.  Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis , 2004, Nature Neuroscience.

[76]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[77]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[78]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[79]  K. Shimazu,et al.  Hyperphosphorylated tau deposition parallels prion protein burden in a case of Gerstmann-Sträussler-Scheinker syndrome P102L mutation complicated with dementia , 2002, Acta Neuropathologica.

[80]  U. Landegren,et al.  Protein detection using proximity-dependent DNA ligation assays , 2002, Nature Biotechnology.

[81]  H. Braak,et al.  Two Types of Sporadic Cerebral Amyloid Angiopathy , 2002, Journal of neuropathology and experimental neurology.

[82]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[83]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[84]  H. Budka,et al.  Marked increase of neuronal prion protein immunoreactivity in Alzheimer's disease and human prion diseases , 2001, Acta Neuropathologica.

[85]  Patrick R. Hof,et al.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.

[86]  H. Braak,et al.  Sequence of Aβ‐Protein Deposition in the Human Medial Temporal Lobe , 2000 .

[87]  K. Blennow,et al.  Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.

[88]  M. Esiri,et al.  Prion protein immunoreactivity in brain samples from an unselected autopsy population: findings in 200 consecutive cases , 2000, Neuropathology and applied neurobiology.

[89]  U. Rüb,et al.  Alzheimer-Related τ-Pathology in the Perforant Path Target Zone and in the Hippocampal Stratum Oriens and Radiatum Correlates with Onset and Degree of Dementia , 2000, Experimental Neurology.

[90]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[91]  G. Jicha,et al.  A Conformation‐ and Phosphorylation‐Dependent Antibody Recognizing the Paired Helical Filaments of Alzheimer's Disease , 1997, Journal of neurochemistry.

[92]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[93]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[94]  M. Goedert,et al.  Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404 , 1994, Journal of neuroscience research.

[95]  K. Jellinger,et al.  Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients , 1993, Neuroscience Letters.

[96]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[97]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[98]  H. Braak,et al.  Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.

[99]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[100]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[101]  H. Wiśniewski,et al.  Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. , 1986, The Journal of biological chemistry.

[102]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[103]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[104]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[105]  A. Misran,et al.  Protein , 2019, Postharvest Physiology and Biochemistry of Fruits and Vegetables.

[106]  S. Strittmatter,et al.  Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5. , 2018, Advances in pharmacology.

[107]  I. Ferrer,et al.  Role of PrPC Expression in Tau Protein Levels and Phosphorylation in Alzheimer’s Disease Evolution , 2014, Molecular Neurobiology.

[108]  N. Hooper,et al.  Prion protein is reduced in aging and in sporadic but not in familial Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[109]  L. Grinberg,et al.  The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset? , 2009, Neuropathology and applied neurobiology.

[110]  H. Cai,et al.  Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[111]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[112]  I. Ferrer,et al.  Prion protein expression in senile plaques in Alzheimer's disease , 2000, Acta Neuropathologica.

[113]  H. Braak,et al.  Sequence of Abeta-protein deposition in the human medial temporal lobe. , 2000, Journal of neuropathology and experimental neurology.

[114]  D. Teplow,et al.  Amyloid beta-peptide is produced by cultured cells during normal metabolism. , 1992, Nature.

[115]  A. Alzheimer.  Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .

[116]  Rena Li,et al.  Amyloid (cid:1) peptide load is correlated with increased (cid:1) -secretase activity in sporadic Alzheimer’s disease patients , 2004 .